Akero Therapeutics, Inc. (AKRO)
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company’s lead product candidate is efruxifermin (EFX).
Brainstorm Cell Therapeutics Inc. (BCLI)
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods.
Social Capital Suvretta Holdings Corp. II (DNAB)
Social Capital Suvretta Holdings Corp. II does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in biotechnology industry.